Trial Profile
Bivalirudin in Patient at High Risk of Bleeding Undergoing Percutaneous Coronary Interventions.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary) ; Heparin
- Indications Cardiovascular disorders; Thromboembolism
- Focus Adverse reactions
- Acronyms NAPLES-III
- 11 Mar 2015 Trial design presented at Cardiovascular Drugs and Therapy.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2011 New trial record